NCT00740727

EASI Access II --- Follow-up Study to the EASI Access Trial

Enzymatically Augmented Subcutaneous Infusion (EASI) Access II Trial

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 18 (actual)
• Sponsor: Massachusetts General Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

Test whether Basic Life Support (BLS) providers can successfully place Enzymatically Augmented Subcutaneous Infusion (EASI) Access lines for subcutaneous infusion, and characterize intravascular absorption of EASI-administered (tracer-labelled) glucose (D5W).

Conditions

• Disaster Medicine
• Difficult Intravenous Access
• Dehydration

Interventions

Type	Name	Description
DRUG	Human recombinant hyaluronidase (HRH)	150u HRH administered via EASI access line, prior to infusion of 250 D5W (5% dextrose in water)
PROCEDURE	Enzymatically Augmented Subcutaneous Infusion (EASI) line placement	Subjects will under placement of an EASI line. This entails placement of a small (20-gauge) catheter in the upper back, in the subcutaneous space.

Timeline

• Start date: 2009-02-01
• Primary completion: 2009-03-01
• Completion: 2009-03-01
• First posted: 2008-08-25
• Last updated: 2009-09-11
• Results posted: 2009-09-11

Locations

1 site across 1 country: United States